請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76741
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 郭明良 | |
dc.contributor.author | Tzu-Hsin Chen | en |
dc.contributor.author | 陳次馨 | zh_TW |
dc.date.accessioned | 2021-07-10T21:36:04Z | - |
dc.date.available | 2021-07-10T21:36:04Z | - |
dc.date.copyright | 2016-10-14 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-07-27 | |
dc.identifier.citation | 1. I. J. Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3, 453-458 (2003).
2. A. F. Chambers, A. C. Groom, I. C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2, 563-572 (2002). 3. I. J. Fidler, The organ microenvironment and cancer metastasis. Differentiation 70, 498-505 (2002). 4. D. F. Quail, J. A. Joyce, Microenvironmental regulation of tumor progression and metastasis. Nat Med 19, 1423-1437 (2013). 5. L. Weiss, Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 19, I-XI, 193-383 (2000). 6. J. A. Joyce, J. W. Pollard, Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252 (2009). 7. F. Balkwill, A. Mantovani, Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). 8. L. M. Coussens, Z. Werb, Inflammation and cancer. Nature 420, 860-867 (2002). 9. J. K. Triantafillidis, G. Nasioulas, P. A. Kosmidis, Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 29, 2727-2737 (2009). 10. K. Fukase et al., Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372, 392-397 (2008). 11. S. C. Chuang, C. La Vecchia, P. Boffetta, Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286, 9-14 (2009). 12. X. Castellsague, Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 110, S4-7 (2008). 13. C. Young, Solar ultraviolet radiation and skin cancer. Occup Med (Lond) 59, 82-88 (2009). 14. J. Cornfield et al., Smoking and lung cancer: recent evidence and a discussion of some questions. 1959. Int J Epidemiol 38, 1175-1191 (2009). 15. J. M. Samet et al., Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Cancer Res 15, 5626-5645 (2009). 16. S. P. Hussain, C. C. Harris, Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121, 2373-2380 (2007). 17. Y. Wu, B. P. Zhou, Inflammation: a driving force speeds cancer metastasis. Cell Cycle 8, 3267-3273 (2009). 18. H. Lu, W. Ouyang, C. Huang, Inflammation, a key event in cancer development. Mol Cancer Res 4, 221-233 (2006). 19. T. Kitamura, B. Z. Qian, J. W. Pollard, Immune cell promotion of metastasis. Nat Rev Immunol 15, 73-86 (2015). 20. J. Schmitz et al., IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490 (2005). 21. S. Tominaga, A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 258, 301-304 (1989). 22. D. Xu et al., Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187, 787-794 (1998). 23. A. J. Coyle et al., Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 190, 895-902 (1999). 24. M. Lohning et al., T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 95, 6930-6935 (1998). 25. S. Sanada et al., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117, 1538-1549 (2007). 26. C. Moussion, N. Ortega, J. P. Girard, The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3, e3331 (2008). 27. A. M. Miller et al., IL-33 reduces the development of atherosclerosis. J Exp Med 205, 339-346 (2008). 28. V. Carriere et al., IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 104, 282-287 (2007). 29. E. S. Baekkevold et al., Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 163, 69-79 (2003). 30. S. Ali et al., The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187, 1609-1616 (2011). 31. T. M. Watters, E. F. Kenny, L. A. O'Neill, Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunol Cell Biol 85, 411-419 (2007). 32. S. Akira, K. Takeda, T. Kaisho, Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2, 675-680 (2001). 33. P. N. Pushparaj et al., The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 106, 9773-9778 (2009). 34. M. Funakoshi-Tago et al., TRAF6 is a critical signal transducer in IL-33 signaling pathway. Cell Signal 20, 1679-1686 (2008). 35. W. C. Gause, T. A. Wynn, J. E. Allen, Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol 13, 607-614 (2013). 36. N. E. Humphreys, D. Xu, M. R. Hepworth, F. Y. Liew, R. K. Grencis, IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 180, 2443-2449 (2008). 37. L. A. Hu, Y. Fu, D. N. Zhang, J. Zhang, Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev 14, 2563-2566 (2013). 38. P. Sun et al., Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 56, 3596-3601 (2011). 39. P. Zhang et al., Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res 40, 1654-1661 (2012). 40. J. Y. Kim et al., Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity. Oncogene 34, 4928-4938 (2015). 41. S. F. Chen et al., The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 231, 180-189 (2013). 42. S. M. Brunner et al., Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. Hepatology 61, 1957-1967 (2015). 43. J. Li et al., Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 124, 3241-3251 (2014). 44. R. L. Maywald et al., IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A 112, E2487-2496 (2015). 45. J. Liu, J. X. Shen, J. L. Hu, W. H. Huang, G. J. Zhang, Significance of interleukin-33 and its related cytokines in patients with breast cancers. Front Immunol 5, 141 (2014). 46. S. Lee et al., Profiling of transcripts and proteins modulated by K-ras oncogene in the lung tissues of K-ras transgenic mice by omics approaches. Int J Oncol 34, 161-172 (2009). 47. X. Gao et al., Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells. J Immunol 194, 438-445 (2015). 48. C. Musolino et al., Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Br J Haematol 160, 709-710 (2013). 49. R. Kalluri, R. A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428 (2009). 50. P. M. Siegel, W. Shu, R. D. Cardiff, W. J. Muller, J. Massague, Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 100, 8430-8435 (2003). 51. M. A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010). 52. W. J. Nelson, R. Nusse, Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303, 1483-1487 (2004). 53. J. Zavadil, L. Cermak, N. Soto-Nieves, E. P. Bottinger, Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23, 1155-1165 (2004). 54. S. S. Karhadkar et al., Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004). 55. E. A. Carver, R. Jiang, Y. Lan, K. F. Oram, T. Gridley, The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol 21, 8184-8188 (2001). 56. P. Savagner, K. M. Yamada, J. P. Thiery, The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition. J Cell Biol 137, 1403-1419 (1997). 57. J. Yang et al., Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004). 58. M. Korpal, E. S. Lee, G. Hu, Y. Kang, The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283, 14910-14914 (2008). 59. M. Korpal, Y. Kang, The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 5, 115-119 (2008). 60. A. Jeanes, C. J. Gottardi, A. S. Yap, Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920-6929 (2008). 61. N. Pecina-Slaus, Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3, 17 (2003). 62. J. Y. Shih et al., Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 11, 8070-8078 (2005). 63. S. Elloul et al., Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103, 1631-1643 (2005). 64. M. Chen, L. M. Chen, K. X. Chai, Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate 66, 911-920 (2006). 65. M. Shioiri et al., Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 94, 1816-1822 (2006). 66. J. Zhang, Q. Cheng, Y. Zhou, Y. Wang, X. Chen, Slug is a key mediator of hypoxia induced cadherin switch in HNSCC: correlations with poor prognosis. Oral Oncol 49, 1043-1050 (2013). 67. C. H. Huang et al., Regulation of membrane-type 4 matrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia 11, 1371-1382 (2009). 68. S. H. Chiou et al., Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70, 10433-10444 (2010). 69. P. Bhat-Nakshatri et al., SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype. BMC Cancer 10, 411 (2010). 70. K. Polyak, R. A. Weinberg, Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273 (2009). 71. Y. W. Chu et al., Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol 17, 353-360 (1997). 72. A. Onn et al., Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9, 5532-5539 (2003). 73. R. E. Hewitt et al., Validation of a model of colon cancer progression. J Pathol 192, 446-454 (2000). 74. K. Morikawa et al., Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48, 6863-6871 (1988). 75. T. Reya, S. J. Morrison, M. F. Clarke, I. L. Weissman, Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001). 76. J. E. Visvader, G. J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755-768 (2008). 77. A. Kreso, J. E. Dick, Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291 (2014). 78. L. Ricci-Vitiani et al., Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007). 79. A. Eramo et al., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15, 504-514 (2008). 80. C. Zhao, S. Setrerrahmane, H. Xu, Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line. Oncol Rep 34, 2126-2132 (2015). 81. T. Klonisch et al., Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol Med 14, 450-460 (2008). 82. M. V. Agrez, J. S. Kovach, M. M. Lieber, Cell aggregates in the soft agar 'human tumour stem-cell assay'. Br J Cancer 46, 880-887 (1982). 83. J. Yang, R. A. Weinberg, Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14, 818-829 (2008). 84. B. Aktas et al., Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11, R46 (2009). 85. A. Gheldof, G. Berx, Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci 116, 317-336 (2013). 86. V. Bolos et al., The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 116, 499-511 (2003). 87. T. Y. Chou et al., Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 21, 704-711 (2009). 88. H. Chen et al., Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 69, 9228-9235 (2009). 89. R. Kakkar, R. T. Lee, The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7, 827-840 (2008). 90. K. Seki et al., Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2, 684-691 (2009). 91. J. Kearley, K. F. Buckland, S. A. Mathie, C. M. Lloyd, Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 179, 772-781 (2009). 92. M. Karin, The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270, 16483-16486 (1995). 93. X. Y. Huang et al., alphaB-crystallin complexes with 14-3-3zeta to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma. Hepatology 57, 2235-2247 (2013). 94. A. Masamune et al., Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 299, G821-832 (2010). 95. M. I. Arshad et al., Oncostatin M induces IL-33 expression in liver endothelial cells in mice and expands ST2+CD4+ lymphocytes. Am J Physiol Gastrointest Liver Physiol 309, G542-553 (2015). 96. J. Jiang, Y. L. Tang, X. H. Liang, EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11, 714-723 (2011). 97. F. Y. Liew, N. I. Pitman, I. B. McInnes, Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10, 103-110 (2010). 98. G. Haraldsen, J. Balogh, J. Pollheimer, J. Sponheim, A. M. Kuchler, Interleukin-33 - cytokine of dual function or novel alarmin? Trends Immunol 30, 227-233 (2009). 99. J. Pollheimer et al., Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol 33, e47-55 (2013). 100. A. G. Dalgleish, K. J. O'Byrne, Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. Adv Cancer Res 84, 231-276 (2002). 101. M. R. Shurin, L. Lu, P. Kalinski, A. M. Stewart-Akers, M. T. Lotze, Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21, 339-359 (1999). 102. K. L. Knutson, M. L. Disis, Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54, 721-728 (2005). 103. L. De Monte et al., Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208, 469-478 (2011). 104. M. Komai-Koma et al., IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 37, 2779-2786 (2007). 105. M. D. Smithgall et al., IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 20, 1019-1030 (2008). 106. T. Pecaric-Petkovic, S. A. Didichenko, S. Kaempfer, N. Spiegl, C. A. Dahinden, Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113, 1526-1534 (2009). 107. C. S. Hardman, V. Panova, A. N. McKenzie, IL-33 citrine reporter mice reveal the temporal and spatial expression of IL-33 during allergic lung inflammation. Eur J Immunol 43, 488-498 (2013). 108. J. L. Barlow et al., IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 132, 933-941 (2013). 109. D. E. Byers et al., Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123, 3967-3982 (2013). 110. J. Kearley et al., Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 42, 566-579 (2015). 111. E. A. Engels, Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther 8, 605-615 (2008). 112. Y. Sekine, H. Katsura, E. Koh, K. Hiroshima, T. Fujisawa, Early detection of COPD is important for lung cancer surveillance. Eur Respir J 39, 1230-1240 (2012). 113. X. J. Chen et al., Correlations between serum IL33 and tumor development: a meta-analysis. Asian Pac J Cancer Prev 15, 3503-3505 (2014). 114. Z. P. Yang et al., The Association of Serum IL-33 and sST2 with Breast Cancer. Dis Markers 2015, 516895 (2015). 115. X. Tong et al., Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol 10, 113-125 (2016). 116. X. X. Yu et al., IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway. Dig Dis Sci 60, 1265-1272 (2015). 117. X. Liu et al., IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 453, 486-492 (2014). 118. W. Jiang et al., Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer 13, 280-287 (2012). 119. S. A. Mani et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008). 120. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010). 121. S. E. Witta et al., Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66, 944-950 (2006). 122. T. H. Chang et al., Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Am J Respir Crit Care Med, (2010). 123. A. M. Haslehurst et al., EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12, 91 (2012). 124. X. L. Ye et al., IL-33-induced JNK pathway activation confers gastric cancer chemotherapy resistance. Oncol Rep 33, 2746-2752 (2015). 125. A. Levescot et al., BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. Cancer Res 74, 2669-2676 (2014). 126. L. Roussel, M. Erard, C. Cayrol, J. P. Girard, Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 9, 1006-1012 (2008). 127. M. Gadina, C. A. Jefferies, IL-33: a sheep in wolf's clothing? Sci STKE 2007, pe31 (2007). 128. C. A. Dinarello, Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147 (1996). 129. A. Werman et al., The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 101, 2434-2439 (2004). 130. M. T. Lotze, K. J. Tracey, High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342 (2005). 131. S. Gardella et al., The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3, 995-1001 (2002). 132. P. Scaffidi, T. Misteli, M. E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191-195 (2002). 133. M. Yu et al., HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26, 174-179 (2006). 134. A. M. Kuchler et al., Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173, 1229-1242 (2008). 135. C. Cayrol, J. P. Girard, IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol 31, 31-37 (2014). 136. J. M. Brown, Tumor hypoxia in cancer therapy. Methods Enzymol 435, 297-321 (2007). 137. L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, D. Shasha, Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7, 492-508 (2002). 138. S. Siva et al., A pattern of early radiation-induced inflammatory cytokine expression is associated with lung toxicity in patients with non-small cell lung cancer. PLoS One 9, e109560 (2014). 139. F. Hu et al., Hypoxia-inducible factor-1alpha and interleukin 33 form a regulatory circuit to perpetuate the inflammation in rheumatoid arthritis. PLoS One 8, e72650 (2013). 140. E. Lefrancais et al., IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A 109, 1673-1678 (2012). 141. C. Cayrol, J. P. Girard, The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 106, 9021-9026 (2009). 142. A. U. Luthi et al., Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31, 84-98 (2009). 143. G. Doring, The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 150, S114-117 (1994). 144. C. T. Pham, Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol 6, 541-550 (2006). 145. B. Korkmaz, T. Moreau, F. Gauthier, Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 90, 227-242 (2008). 146. R. A. Stockley, Neutrophils and the pathogenesis of COPD. Chest 121, 151S-155S (2002). 147. N. Vaguliene, M. Zemaitis, S. Lavinskiene, S. Miliauskas, R. Sakalauskas, Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. BMC Immunol 14, 36 (2013). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76741 | - |
dc.description.abstract | 癌症轉移是指癌細胞從體內原來的地方擴散到另外一個部位,為主要造成癌症病人死亡的主因。找出抑制腫瘤轉移之分子並了解其分子機制,可以做為診斷的參考與治療的標靶。細胞介素-33 (Interleukin-33)為細胞介素-1家族的成員之一,透過與受體ST2L的結合調控下游訊號通路。IL-33在恆定的情況下表現於多種類型的細胞和組織,但在發炎反應的過程中其表現量會增加。有許多研究探討IL-33在免疫細胞與癌細胞中扮演重要的角色,但在癌症進展中的作用仍有爭議需進一步探討。在我們的研究中發現IL-33促進細胞的移動性、癌幹細胞特性、非貼附依存性生長和轉移能力。在癌細胞的機制探討發現,經由IL-33的增加人蝸牛同源物2 (Slug)表現量進而影響細胞上皮-間質轉化(EMT)而有形態學上的改變,同時也促進癌細胞的移行性和浸襲性。進一步探討IL-33如何調控Slug發現,IL-33透過與受體ST2L的結合,促進下游的ERK訊息傳遞,經由c-Jun/Fra-1的調控增加Slug的表現量。此外,過去研究證實缺氧的狀態下會促進癌細胞上皮-間質轉化,進而增加癌細胞浸襲性與腫瘤轉移。在我們的研究顯示當癌細胞面臨缺氧環境時,可能因增加了IL-33調控Slug路徑的活化,促進癌細胞的轉移。另外,我們也發現了IL-33是具有雙重作用的因子,會因其分佈的位置而有不同的作用。全長的IL-33主要在細胞核內降低癌細胞的細胞移行和浸襲能力,但當IL-33釋放到細胞外則促進腫瘤的發展。因此,細胞外的IL-33可做為未來治療癌症轉移之一有潛力的標靶與臨床診斷的評估指標。 | zh_TW |
dc.description.abstract | Metastasis is the most important contributor to mortality in cancer patients. Identification of tumor metastasis mediator and elucidation of the molecular mechanism contributes to development of cancer targeted therapies. Interleukin-33 (IL-33), a member of the IL-1 family, was identified as the ligand for IL-1 receptor-related protein ST2L. Although IL-33 is universally expressed in tissues during homeostasis, its expression can be up-regulated in the process of inflammation. Growing evidence suggests that IL-33 plays important roles in immune cells and tumor cells, but the controversial roles of IL-33 in cancer progression remains to be investigated. In this study, we demonstrated that IL-33 promotes cancer cell mobility, sphere formation, anchorage-independent growth, and tumor metastasis. We also found that IL-33 enhances the migratory and invasive capabilities of cancer cells by inducing epithelial-to-mesenchymal transition (EMT) through upregulation of zinc-finger protein Slug. Further evidence has showed that IL-33 may induce Slug expression through ST2L-ERK-c-Jun/Fra-1 signaling in cancer cells. Moreover, hypoxia had been reported to promote the invasion and metastasis of cancer cells via a process of EMT. Our results showed that hypoxia may enhance IL-33/ST2L–mediated ERK-c-Jun/Fra-1-Slug signaling resulting in cancer metastasis. Furthermore, we demonstrated that IL-33 has a dual function depending on the cellular localization. Full-length IL-33 is mainly localized in nucleus, and represses cancer cell migration and invasion. However, extracellular IL-33–driven cancer cell mobility and tumor metastasis, may act as a potential therapeutic target and a biomarker for cancer therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T21:36:04Z (GMT). No. of bitstreams: 1 ntu-105-R03b46010-1.pdf: 4214702 bytes, checksum: 6270dde8d6247907681037546c9149a2 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員審定書...........................................I
誌謝...................................................II 中文摘要...............................................III Abstract...............................................IV Chapter1. Introduction..................................1 1.1 Tumor metastasis....................................2 1.2 Inflammation and cancer progression.................3 1.3 Interleukin-33 (IL-33)..............................4 1.4 Epithelial-to-mesenchymal transition (EMT) and Slug.6 1.5 Motivation and purpose..............................8 Chapter2. Materials and Methods.........................9 Chapter3. Results......................................17 3.1 IL-33 is up-regulation in highly invasive and metastatic cancer cells................................18 3.2 IL-33 enhances cancer cell migration and invasion...............................................18 3.3 IL-33 promotes cancer cell stemness and anchorage-independent growth.....................................19 3.4 IL-33 promotes epithelial-to-mesenchymal transition by inducing Slug through ERK signaling.................20 3.5 IL-33 enhances ERK activation and epithelial-to-mesenchymal transition depending on ST2L receptor......22 3.6 The ERK-c-Jun/Fra-1 axis regulates Slug expression.23 3.7 Hypoxia induces IL-33 expression and transcriptional activation of ST2L-c-Jun/Fra-1-Slug axis...............24 3.8 IL-33 is a dual function cytokine in tumor metastasis.............................................24 3.9 Secreted IL-33 effectively promotes tumor metastasis in an orthotopic animal model..........................26 Chapter4. Discussion...................................27 Figures and Figure Legends.............................33 Tables.................................................60 References.............................................65 | |
dc.language.iso | en | |
dc.title | 探討細胞介素-33在癌症進程中所扮演的角色 | zh_TW |
dc.title | Evaluation the Role of Interleukin-33 (IL-33) in Cancer Progression | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 華國泰,蕭宏昇,洪文俊,張震東 | |
dc.subject.keyword | 細胞介素33,上皮到間質轉化,人蝸牛同源物2,浸襲,轉移,缺氧, | zh_TW |
dc.subject.keyword | IL-33,epithelial-mesenchymal transition,Slug,invasion,metastasis,hypoxia, | en |
dc.relation.page | 75 | |
dc.identifier.doi | 10.6342/NTU201601262 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2016-07-27 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-R03b46010-1.pdf 目前未授權公開取用 | 4.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。